The role of pharmacoeconomics in formulary decision making in different hospitals in Riyadh, Saudi Arabia

Saudi Pharmaceutical Journal

Volumn 19, Issue 1, 2011, Pages 51-56

  Alsultan, Mohammed S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Formulary decision; Pharmacoeconomics; Pharmacy and Therapeutics committees; Saudi Arabia

Indexed keywords

ADULT; ARTICLE; CLINICAL DECISION MAKING; DRUG FORMULARY; HOSPITAL ADMINISTRATOR; HUMAN; MEDICAL EDUCATION; PHARMACIST; PHARMACOECONOMICS; PHARMACY AND THERAPEUTICS COMMITTEE; PHYSICIAN; SAUDI ARABIA; STRUCTURED QUESTIONNAIRE; WORKSHOP;

EID: 78650620314     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2010.10.005     Document Type: Article

References (30)

1. Abou-Auda H. An economic assessment of the extent of medication use and wastage among families in Saudi Arabia and Arabia gulf countries. Clin. Ther. 2003, 25:1276-1292.
2. Academy of Managed Care Pharmacy (AMCP) Position Statement on Formularies 1997, Academy of Managed Care Pharmacy, Alexandria, VA.
3. American Society of Health-System Pharmacists (ASHP) Statement on the formulary system. Practice Standard of ASHP 1995, American Society of Health-System Pharmacists, Bethesda, MD. W.E. Hicks (Ed.).
4. American Society of Health-System Pharmacists (ASHP) Statement on the pharmacy and therapeutics committee and the formulary system. Am. J. Hosp. Pharm. 2008, 65:2384-2386.
5. Arenas R., Tosti A., Hay R., Haneke E. Pharmacoeconomics - an aid to better decision-making. JEADV 2005, 19:34-39.
6. Armstrong K., Mitton C., Carleton B., Shoveller J. Drug formulary decision-making in two regional health authorities in British Columbia, Canada. Health Policy 2008, 88:308-316.
7. Baluch W., Gardner J., Krauss R., Scholes D. Therapeutic interchange of conjugated and esterified estrogens in a managed care organization. Am. J. Health Syst. Pharm. 1999, 56:537-542.
8. Bentkover J., Corey R. Effective utilization of pharmacoeconomics for decision makers. Dis. Manage. Health Outcomes 2002, 10:75-80.
9. Centers for Medicare and Medicaid Services (CMS), 2010. Health accounts. (accessed on 08.06.2010). http://www.cms.gov/statistics/nhe/.
10. Eddama O., Coast J. Use of economic evaluation in local health care decision-making in England: a qualitative investigation. Health Policy 2009, 89:261-270.
11. Eddama O., Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy 2008, 86:129-141.
12. Green E., Chrymko M., Rozek S., Kitrenos J. Clinical considerations and costs associated with formulary conversion from tobramycin to gentamicin. Am. J. Hosp. Pharm. 1989, 46:714-719.
13. Hans M., Marie C., Magali M., Marie C. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm. World Sci. 2003, 25:269-275.
14. Harris A. Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries. Expert Rev. Pharmacoeconom. Outcomes Res. 2001, 1:7-12.
15. Hazlet T., Hu T. Association between formulary strategies and hospital drug expenditures. Am. J. Hosp. Pharm. 1992, 49:2207-2210.
16. Jacobs P., Bachynsky J., Baladi J. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995, 8:182-189.
17. Kozma C., Reeder C., Schulz R. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin. Ther. 1993, 15:1121-1132.
18. Lyles A., Luce B., Rentz A. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Soc. Sci. Med. 1997, 45:511-521.
19. Motheral B., Grizzle A., Armstrong E., Cox E., Fairman K. Role of pharmacoeconomics in drug benefit decision-making: results of a survey. Formulary 2000, 35:412-442.
20. Mullins C., Wang J. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision-making. Pharmacoeconomics 2002, 20:9-21.
21. Odedina F., Sullivan J., Nash R., Clemmons C. Use of pharmacoeconomic data in making hospital formulary decisions. Am. J. Health Syst. Pharm. 2002, 59:1441-1444.
22. Organization for Economic Co-Operation and Development (OECD) Health Data, 2003. Online. <> (accessed on 13.05.2010). http://www.oecd.org/document/39/0,2340,en_2649_201185_2789735_1_1_1_1,1,00.html.
23. Organization for Economic Co-Operation and Development (OECD) Health Data, 2009. Online. <> (accessed 13.05.2010). http://www.oecd.org/document/16/0,3343,en_2649_34631_2085200_1_1_1_1,00.html.
24. Quinn C., Barisano A. Understanding, creating, and working with formulary systems. Am. J. Manage. Care 1999, 5:1311-1317.
25. Saudi Arabia, 2008. Healthcare and pharmaceuticals forecast (market profile). (accessed on 28.08.2008). http://www.zawya.com/printstory.cfm?storyid=EIU20081101211439546&l=000000080828.
26. Shah N., Hoffman J., Vermeulen L., Hunkler R., Hontz K. Projecting future drug expenditures 2003. Am. J. Health Syst. Pharm. 2003, 60:137-149.
27. Suh D., Okpara I., Agnese W., Toscani M. Application of pharmacoeconomics to formulary decision making in managed care organizations. Am. J. Manage. Care 2002, 8:161-169.
28. Tordoff J., Murphy J., Norris P., Reith D. Use of centrally developed pharmacoeconomic assessments for local formulary decisions. Am. J. Health Syst. Pharm. 2006, 63:1613-1618.
29. Vuornkoski L., Toivianen H., Hemminki E. Decision-making in priority setting for medicines-a review of empirical studies. Health Policy 2008, 86:1-9.
30. Williams I., Bryan S. Cost-effectiveness analysis and formulary decision making in England: findings from research. Soc. Sci. Med. 2007, 65:2116-2129.